Latest Commercial Execution News

EVE Health Group has progressed its Libbo pilot clinical study for erectile dysfunction with dosing set for Q4 2026 and achieved a major solubility breakthrough for apixaban, while appointing Ben Rohr as CEO to drive commercial growth.

Rimfire Pacific Mining has appointed Bronwyn Barnes as Executive Chair and secured $2.3 million in a placement to advance its scandium exploration and development strategy.

AVITA Medical posted robust Q2 2026 results with 18% revenue growth, driven by RECELL and supported by Cohealyx and PermeaDerm, and now expects to reach cash flow breakeven by year-end.

Micro-X has named Brian Gonzales as its new CEO, initiating a strategic reset focused on medical CT technology. The company also secured $8 million in convertible note commitments to fund development and extend its financial runway through FY27.

Iondrive has launched its first five-tonne IONSolv™ production campaign in North America, aiming to produce about 1.4 tonnes of mixed rare earth oxide from recycled permanent magnets by Q4 2026. This milestone bridges lab validation and commercial-scale plans while supporting US supply chain independence.

Ava Risk Group has appointed Bryant Henson as CEO to spearhead its next growth phase, with a sharp focus on expanding its footprint in the United States and strengthening commercial execution worldwide.

Peppermint Innovation Ltd (ASX:PIL) reported a 171% jump in group revenue for the June quarter, powered by a 577% surge in its Bizmoto revenue and a successful pilot of its QRPh Person-to-Merchant payment platform that tripled monthly transaction values. The company is advancing its ASX reinstatement while expanding its digital payments ecosystem in the Philippines.

IMEXHS Limited posted a 21% revenue increase in Q2 FY26, driven by a landmark public tender in Mexico deploying its AI-powered Aquila+ radiology platform. The company’s proprietary AI agents are now operational in live environments, supporting its strategy to own the full radiology workflow.

Decidr AI Industries accelerated its commercial growth with a 71% jump in annualised exit-rate revenue to $13.6 million and bolstered its cash position to $23.4 million following a $14.2 million equity raise.

Janus Electric navigated a transitional Q4 FY26 by settling legacy debts, raising $12 million, and growing its North American order book to 112 truck conversions, positioning itself for commercial scale-up.

BCAL Diagnostics has strengthened its leadership, advanced breast cancer detection tests, and secured key funding and strategic investments to underpin its FY2027 growth plans.

Rhythm Biosciences bolstered its financial position with a $5.2 million option underwriting while accelerating commercial adoption of its ColoSTAT® colorectal cancer test and advancing geneType™ partnerships internationally in Q4 FY26.